168 related articles for article (PubMed ID: 3285804)
1. Cycloplatam and oxoplatin--the new antitumor platinum compounds of the second generation.
Presnov MA; Konovalova AL
Arch Geschwulstforsch; 1988; 58(1):43-9. PubMed ID: 3285804
[TBL] [Abstract][Full Text] [Related]
2. In vivo and in vitro effectivity of some platinum complexes.
Balázová E; Hrubisko M; Ujházy V
Neoplasma; 1984; 31(6):641-7. PubMed ID: 6395026
[TBL] [Abstract][Full Text] [Related]
3. The antitumor activity of oxoplatinum.
Presnov MA; Konovalova AL; Kozlov AM; Brovtsyn VK; Romanova LF
Neoplasma; 1985; 32(1):73-83. PubMed ID: 4039040
[TBL] [Abstract][Full Text] [Related]
4. [Comparative study of platinum complexes in athymic mice with human tumors].
Bukharov IK; Osokina LI; Revazova ES; Moroz LV
Vopr Onkol; 1988; 34(9):1084-7. PubMed ID: 3188435
[TBL] [Abstract][Full Text] [Related]
5. [Structure-activity relations of antineoplastic platinum II and platinum IV coordination compounds].
Gutsche W; Baumgart J; Schröer HP
Arch Geschwulstforsch; 1989; 59(4):233-8. PubMed ID: 2802931
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of a new platinum complex, 2-aminomethyl-pyrrolidine (1, 1-cyclobutanedicarboxylato) platinum (II).
Endoh K; Akamatsu K; Matsumoto T; Morikawa K; Honda M; Mitsui H; Koizumi M; Koizumi K; Matsuno T
Anticancer Res; 1989; 9(4):987-91. PubMed ID: 2817826
[TBL] [Abstract][Full Text] [Related]
7. Novel trans platinum complexes: comparative in vitro and in vivo activity against platinum-sensitive and resistant murine tumours.
Goddard PM; Orr RM; Valenti MR; Barnard CF; Murrer BA; Kelland LR; Harrap KR
Anticancer Res; 1996; 16(1):33-8. PubMed ID: 8615631
[TBL] [Abstract][Full Text] [Related]
8. [Antitumor effect of carboplatin and iproplatin on human urinary bladder and prostatic cancers grown in nude mice].
Hasegawa J; Kawamura N; Yamada S; Tsuboi N; Akimoto M
Gan To Kagaku Ryoho; 1987 Dec; 14(12):3279-83. PubMed ID: 3318705
[TBL] [Abstract][Full Text] [Related]
9. Cycloplatam: a novel platinum compound exhibiting a different spectrum of anti-tumour activity to cisplatin.
Drees M; Dengler WM; Hendriks HR; Kelland LR; Fiebig HH
Eur J Cancer; 1995; 31A(3):356-61. PubMed ID: 7786602
[TBL] [Abstract][Full Text] [Related]
10. [Antitumor activity and toxicity of KB-5424 R, a newly developed antitumor platinum compound].
Yamaguchi H; Kubota T; Takahara T; Takeuchi T; Furukawa T; Kase S; Josui K; Kodaira S; Ishibiki K; Abe O
Gan To Kagaku Ryoho; 1991 Jun; 18(7):1135-41. PubMed ID: 2053772
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effects of three platinum complexes, (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato)-platinum (II) monohydrate (DWA2114R), cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) (CBDCA) and cis-diamminedichloroplatinum(II) (CDDP), in mice.
Endo K; Akamatsu K; Matsumoto T; Morikawa K; Koizumi M; Mitsui H; Koizumi K
Anticancer Res; 1992; 12(1):49-58. PubMed ID: 1567181
[TBL] [Abstract][Full Text] [Related]
12. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
13. Comparative activity and distribution studies of five platinum analogues in nude mice bearing human ovarian carcinoma xenografts.
Boven E; van der Vijgh WJ; Nauta MM; Schlüper HM; Pinedo HM
Cancer Res; 1985 Jan; 45(1):86-90. PubMed ID: 4038381
[TBL] [Abstract][Full Text] [Related]
14. Platinum compounds in the treatment of advanced breast cancer.
Martín M
Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
[TBL] [Abstract][Full Text] [Related]
15. Resistance and cross-resistance of the IgM immunocytoma in the LOU/M Wsl rat for cisplatin, carboplatin, and iproplatin.
Steerenberg PA; Vendrik CP; de Jong WH; de Groot G; Fichtinger-Schepman AM; Scheefhals AP; Schornagel JH
Cancer Chemother Pharmacol; 1988; 22(1):51-7. PubMed ID: 3293840
[TBL] [Abstract][Full Text] [Related]
16. Preclinical studies identifying carboplatin as a viable cisplatin alternative.
Harrap KR
Cancer Treat Rev; 1985 Sep; 12 Suppl A():21-33. PubMed ID: 3910219
[TBL] [Abstract][Full Text] [Related]
17. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
Kelland LR; Abel G; McKeage MJ; Jones M; Goddard PM; Valenti M; Murrer BA; Harrap KR
Cancer Res; 1993 Jun; 53(11):2581-6. PubMed ID: 8388318
[TBL] [Abstract][Full Text] [Related]
18. The effect of platinum cytostatics on delayed-type hypersensitivity in mice.
Jílek P; Dvoráková J; Turecková J; Procházková J
Neoplasma; 1989; 36(6):659-65. PubMed ID: 2693976
[TBL] [Abstract][Full Text] [Related]
19. Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates.
Kelland LR; Mistry P; Abel G; Loh SY; O'Neill CF; Murrer BA; Harrap KR
Cancer Res; 1992 Jul; 52(14):3857-64. PubMed ID: 1617660
[TBL] [Abstract][Full Text] [Related]
20. Preclinical antitumor and toxicologic profile of carboplatin.
Rose WC; Schurig JE
Cancer Treat Rev; 1985 Sep; 12 Suppl A():1-19. PubMed ID: 3910215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
